Twitter LinkedIn
    Friday, January 27
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Fundraising»Abingworth raises USD582m for new Clinical Co-Development Fund, ACCD 2
    Fundraising

    Abingworth raises USD582m for new Clinical Co-Development Fund, ACCD 2

    May 10, 20211 Min Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Abingworth, an international life sciences investment group, has held the final closing of its new Clinical Co-Development Fund at USD582 million.

    Abingworth Clinical Co-Development Fund 2 (ACCD 2) was significantly oversubscribed, exceeding its target of USD350 million, and closed at its hard cap. Alongside the recent USD465 million Abingworth Bioventures 8 (ABV 8) fund, Abingworth has raised over USD1 billion in new funds to invest in life science companies in the US, UK and Continental Europe developing innovative therapeutics with potential to significantly improve human health.

    The ACCD 2 fund provides finance for the development of late-stage clinical programmes from pharmaceutical and biotechnology companies. ACCD 2 will invest directly in late-stage product financing opportunities, as well as through its co-development portfolio companies Avillion (UK) and SFJ Pharmaceuticals (US).

    Read more at Private Equity Wire

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    funds
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    CAI raises over $1B for inaugural fund and co-investment programme

    November 18, 2022

    Carlyle targeting $1.6B for second renewables fund

    November 18, 2022

    Vista’s latest flagship fund halfway to $20B target

    November 18, 2022

    MVM closes oversubscribed Fund VI at $500m hard cap

    November 17, 2022

    Comments are closed.

    Other Articles

    AI software firm 6sense valued at $5.2bn after SoftBank joins funding round

    January 21, 2022

    Vistra launches SPAC and de-SPAC services

    August 8, 2021

    Uber’s Careem Seeks $500m From Abu Dhabi and Saudi Funds

    March 10, 2022

    TC Energy, ex-Columbia Pipeline execs must face lawsuit over $10 billion deal

    March 2, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?